Literature DB >> 26622513

Reduction of the systemic inflammatory induced by acute cerebral infarction through ultra-early thrombolytic therapy.

Lichao Ye1, Ruowei Cai1, Meili Yang1, Jiaqiang Qian1, Zhilin Hong1.   

Abstract

Acute ischemic stroke induces systemic inflammation, exhibited as changes in body temperature, white blood cell counts and C-reactive protein (CRP) levels. The aim of the present study was to observe the effects of intravenous thrombolytic therapy on inflammatory indices in order to investigate the hypothesis that post-stroke systemic inflammatory response occurs in response to the necrosis of brain tissues. In this study, 62 patients with acute cerebral infarction and indications for intravenous thrombolysis were divided into three groups on the basis of their treatment and response: Successful thrombolysis (n=36), failed thrombolysis (n=12) and control (n=14) groups. The body temperature, white blood cell counts and high-sensitivity (hs)-CRP levels were recorded pre-treatment and on post-stroke days 1, 3, 5 and 7. Spearman's correlation analysis showed that the pre-treatment National Institutes of Health Stroke Scale (NIHSS) score positively correlated with body temperature, white blood cell count and hs-CRP levels. On day 3 of effective intravenous thrombolysis, the body temperature and white blood cell were decreased and on days 3 and 5, the serum levels of hs-CRP were reduced compared with those in the failed thrombolysis and control groups. The results indicate that the systemic inflammatory response following acute cerebral infarction was mainly caused by ischemic injury of local brain tissue; the more serious the stroke, the stronger the inflammatory response. Ultra-early thrombolytic therapy may inhibit the necrosis of brain tissue and thereby reduce the inflammatory response.

Entities:  

Keywords:  C-reactive protein; body temperature; infarction; inflammation; thrombolytic therapy; white blood cell

Year:  2015        PMID: 26622513      PMCID: PMC4577940          DOI: 10.3892/etm.2015.2672

Source DB:  PubMed          Journal:  Exp Ther Med        ISSN: 1792-0981            Impact factor:   2.447


  33 in total

1.  Influence of admission body temperature on stroke mortality.

Authors:  Y Wang; L L Lim; C Levi; R F Heller; J Fisher
Journal:  Stroke       Date:  2000-02       Impact factor: 7.914

2.  Hyperthermia is a surrogate marker of inflammation-mediated cause of brain damage in acute ischaemic stroke.

Authors:  R Leira; M Rodríguez-Yáñez; M Castellanos; M Blanco; F Nombela; T Sobrino; I Lizasoain; A Dávalos; J Castillo
Journal:  J Intern Med       Date:  2006-10       Impact factor: 8.989

3.  C-reactive protein is related to extent and progression of coronary and extra-coronary atherosclerosis; results from the Rotterdam study.

Authors:  Suzette E Elias-Smale; Isabella Kardys; Matthijs Oudkerk; Albert Hofman; Jacqueline C M Witteman
Journal:  Atherosclerosis       Date:  2007-08-21       Impact factor: 5.162

4.  Dynamics of polymorphonuclear leukocyte accumulation in acute cerebral infarction and their correlation with brain tissue damage.

Authors:  S E Akopov; N A Simonian; G S Grigorian
Journal:  Stroke       Date:  1996-10       Impact factor: 7.914

5.  Admission body temperature predicts long-term mortality after acute stroke: the Copenhagen Stroke Study.

Authors:  L P Kammersgaard; H S Jørgensen; J A Rungby; J Reith; H Nakayama; U J Weber; J Houth; T S Olsen
Journal:  Stroke       Date:  2002-07       Impact factor: 7.914

6.  Systemic inflammatory response depends on initial stroke severity but is attenuated by successful thrombolysis.

Authors:  Heinrich J Audebert; Michaela M Rott; Thomas Eck; Roman L Haberl
Journal:  Stroke       Date:  2004-07-22       Impact factor: 7.914

7.  The impact of inflammation on the pathogenesis and prognosis of ischemic stroke.

Authors:  Taizen Nakase; Takashi Yamazaki; Naoko Ogura; Akifumi Suzuki; Ken Nagata
Journal:  J Neurol Sci       Date:  2008-05-13       Impact factor: 3.181

8.  Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.

Authors:  H P Adams; B H Bendixen; L J Kappelle; J Biller; B B Love; D L Gordon; E E Marsh
Journal:  Stroke       Date:  1993-01       Impact factor: 7.914

Review 9.  The implementation of intravenous tissue plasminogen activator in acute ischaemic stroke--a scientific position statement from the National Stroke Foundation and the Stroke Society of Australasia.

Authors: 
Journal:  Intern Med J       Date:  2009-05       Impact factor: 2.048

10.  An early rise in body temperature is related to unfavorable outcome after stroke: data from the PAIS study.

Authors:  Heleen M den Hertog; H Bart van der Worp; H Maarten A van Gemert; Ale Algra; L Jaap Kappelle; Jan van Gijn; Peter J Koudstaal; Diederik W J Dippel
Journal:  J Neurol       Date:  2010-09-30       Impact factor: 4.849

View more
  3 in total

1.  Clinical significance and efficacy analysis of atorvastatin in the treatment of patients with cerebral infarction and aspiration pneumonia.

Authors:  Bing Wei; Yugeng Liu
Journal:  Exp Ther Med       Date:  2018-10-04       Impact factor: 2.447

2.  Predictors for symptomatic intracranial hemorrhage after intravenous thrombolysis with acute ischemic stroke within 6 h in northern China: a multicenter, retrospective study.

Authors:  Yuan Xue; Shan Li; Yuanyuan Xiang; Ziran Wang; Fengyun Wang; Yuanying Yu; Peng Yan; Xiaohui Liu; Qinjian Sun; Yifeng Du; Jifeng Li
Journal:  BMC Neurol       Date:  2022-01-03       Impact factor: 2.474

3.  Successful thrombolytic therapy is associated with increased granulocyte CD15 expression and reduced stroke-induced immunosuppression.

Authors:  Katalin Anna Béres-Molnár; Ágnes Czeti; Ferenc Takács; Gábor Barna; Dániel Kis; Gabriella Róka; András Folyovich; Gergely Toldi
Journal:  Brain Behav       Date:  2022-09-16       Impact factor: 3.405

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.